Business
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
TSX Venture: QPT EDMONTON, June 25 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "C...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nTSX Venture: QPT\n\n\nEDMONTON, June 25 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or\nthe "Company"), today announced interim results from its Phase I/II clinical\nstudy designed to investigate appropriate treatment parameters for the\npotential use of its proprietary compound SL017 for hair removal applications.\nThe interim results represent data from the first 80 patients enrolled in the\ntargeted 100-patient clinical trial.\n\n\n"The Phase I/II interim results demonstrated that SL017 is safe and well\ntolerated when used either alone or in combination with photo activation,"\nsaid Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along\nwith results from the previous clinical trial, support the utility of SL017\nfor hair removal applications, especially for those who do not benefit from\nlight treatment alone."\n\n\nTo permanently remove unwanted hair, existing laser hair removal\ntechniques require four to eight treatments, and provide only a 75 to 85\npercent permanent hair reduction in a limited patient population. The\nprofessional laser hair removal market is estimated to be $5 billion\nworldwide.\n\n\nQuest is developing SL017 photodynamic therapy (PDT) as a potential hair\nremoval solution that is effective across a broad patient population including\nthose with light colored hair (for example, grey or blonde hair). In a Phase I\nclinical trial, Quest demonstrated the preferential localization of SL017 in\nhair follicles, which suggested that cutaneous PDT with SL017 has potential\nfor permanent hair removal applications.\n\n\nThe Phase I/II trial of SL017 was designed to evaluate the effect of skin\ntreatment on follicular uptake of SL017, assess the tolerable light dose on\nhealthy subjects, and subsequently, determine the efficacy of hair removal\nunder optimal treatment conditions. Results from this study will be used to\nguide the design of future clinical development.\n\n\nSkin Pretreatment and Follicular Uptake\n\n\nThirty healthy subjects were enrolled to evaluate the efficacy of five\ndifferent skin preparation techniques to enhance the follicular localization\nof SL017. One of the five skin pretreatments demonstrated a statistically\nsignificant improvement in both the intensity of follicular uptake of SL017\nand the depth of penetr...